Tag: Characterized Oral Desensitization ImmunoTherapy (CODIT™)

Aimmune + Xencor

Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development...

News Wire ~ 3rd Party Press Release -
“In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune’s global leadership in the evolving therapeutic landscape of food allergy treatments.”
Eggs

Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for...

News Wire ~ 3rd Party Press Release -
AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.
SnackSafely.com

Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.

We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.

Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.

Please see our Terms of service and Privacy Policy.

SnackSafely.com, PO Box 141, Hillsdale, NJ 07642

©2020 SnackSafely.com Inc. All rights reserved.